Generic Rezdiffra Availability

Last updated on Apr 10, 2025.

Rezdiffra is a brand name of resmetirom, approved by the FDA in the following formulation(s):

REZDIFFRA (resmetirom - tablet;oral)

• Manufacturer: MADRIGAL
  Approval date: March 14, 2024
  Strength(s): 100MG ^[RLD], 60MG ^[RLD], 80MG ^[RLD]

Is there a generic version of Rezdiffra available?

No. There is currently no therapeutically equivalent version of Rezdiffra available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rezdiffra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Methods of synthesizing thyroid hormone analogs and polymorphs thereof
  Patent 10,376,517
  Issued: August 13, 2019
  Inventor(s): Taub; Rebecca et al.
  Assignee(s): Madrigal Pharmaceuticals, Inc. (West Conshohocken, PA); Hoffmann-La Roche Inc. (Little Falls, NJ)
  

  The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TRβ mutation.

  Patent expiration dates:

  • September 17, 2033
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS)
• Methods of synthesizing thyroid hormone analogs and polymorphs thereof
  Patent 11,564,926
  Issued: January 31, 2023
  Inventor(s): Hester, II; D. Keith et al.
  Assignee(s): Madrigal Pharmaceuticals, Inc. (West Conshohocken, PA); Hoffmann-La Roche Inc. (Little Falls, NJ)
  

  The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TRβ mutation.

  Patent expiration dates:

  • September 17, 2033
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS)
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Method of synthesizing thyroid hormone analogs and polymorphs thereof
  Patent 11,986,481
  Issued: May 21, 2024
  Inventor(s): Kelly; Martha J. et al.
  Assignee(s): Madrigal Pharmaceuticals, Inc. (West Conshohocken, PA); Hoffmann-La Roche Inc. (Little Falls, NJ)
  

  The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TRβ mutation.

  Patent expiration dates:

  • September 17, 2033
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS)
• Thyroid hormone analogs
  Patent 7,452,882
  Issued: November 18, 2008
  Inventor(s): Haynes; Nancy-Ellen et al.
  Assignee(s): Hoffmann-La Roche Inc. (Nutley, NJ)
  

  Provided herein are compounds of the formula (I): ##STR00001## as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto.

  Patent expiration dates:

  • September 12, 2026
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Method of synthesizing thyroid hormone analogs and polymorphs thereof
  Patent 9,266,861
  Issued: February 23, 2016
  Inventor(s): Hester, II; D. Keith et al.
  Assignee(s): Madrigal Pharmaceuticals, Inc. (Fort Washington, PA); Hoffmann-La Roche Inc. (Nutley, NJ)
  

  The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TRβ mutation.

  Patent expiration dates:

  • September 17, 2033
    
    ✓ 
    Drug substance
    ✓ 
    Drug product

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • March 14, 2029 - NEW CHEMICAL ENTITY

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer